Ovarian Cancer: Opportunity for Targeted Therapy
Ovarian cancer is a common cause of cancer mortality in women with limited treatment effectiveness in advanced stages. The limitation to treatment is largely the result of high rates of cancer recurrence despite chemotherapy and eventual resistance to existing chemotherapeutic agents. The objective...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2012/682480 |
id |
doaj-e1f108e119f740ac86c2140aa8317a76 |
---|---|
record_format |
Article |
spelling |
doaj-e1f108e119f740ac86c2140aa8317a762020-11-24T22:28:07ZengHindawi LimitedJournal of Oncology1687-84501687-84692012-01-01201210.1155/2012/682480682480Ovarian Cancer: Opportunity for Targeted TherapyTomoko Tagawa0Robert Morgan1Yun Yen2Joanne Mortimer3Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USADepartment of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USAOvarian cancer is a common cause of cancer mortality in women with limited treatment effectiveness in advanced stages. The limitation to treatment is largely the result of high rates of cancer recurrence despite chemotherapy and eventual resistance to existing chemotherapeutic agents. The objective of this paper is to review current concepts of ovarian carcinogenesis. We will review existing hypotheses of tumor origin from ovarian epithelial cells, Fallopian tube, and endometrium. We will also review the molecular pathogenesis of ovarian cancer which results in two specific pathways of carcinogenesis: (1) type I low-grade tumor and (2) type II high-grade tumor. Improved understanding of the molecular basis of ovarian carcinogenesis has opened new opportunities for targeted therapy. This paper will also review these potential therapeutic targets and will explore new agents that are currently being investigated.http://dx.doi.org/10.1155/2012/682480 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tomoko Tagawa Robert Morgan Yun Yen Joanne Mortimer |
spellingShingle |
Tomoko Tagawa Robert Morgan Yun Yen Joanne Mortimer Ovarian Cancer: Opportunity for Targeted Therapy Journal of Oncology |
author_facet |
Tomoko Tagawa Robert Morgan Yun Yen Joanne Mortimer |
author_sort |
Tomoko Tagawa |
title |
Ovarian Cancer: Opportunity for Targeted Therapy |
title_short |
Ovarian Cancer: Opportunity for Targeted Therapy |
title_full |
Ovarian Cancer: Opportunity for Targeted Therapy |
title_fullStr |
Ovarian Cancer: Opportunity for Targeted Therapy |
title_full_unstemmed |
Ovarian Cancer: Opportunity for Targeted Therapy |
title_sort |
ovarian cancer: opportunity for targeted therapy |
publisher |
Hindawi Limited |
series |
Journal of Oncology |
issn |
1687-8450 1687-8469 |
publishDate |
2012-01-01 |
description |
Ovarian cancer is a common cause of cancer mortality in women with limited treatment effectiveness in advanced stages. The limitation to treatment is largely the result of high rates of cancer recurrence despite chemotherapy and eventual resistance to existing chemotherapeutic agents. The objective of this paper is to review current concepts of ovarian carcinogenesis. We will review existing hypotheses of tumor origin from ovarian epithelial cells, Fallopian tube, and endometrium. We will also review the molecular pathogenesis of ovarian cancer which results in two specific pathways of carcinogenesis: (1) type I low-grade tumor and (2) type II high-grade tumor. Improved understanding of the molecular basis of ovarian carcinogenesis has opened new opportunities for targeted therapy. This paper will also review these potential therapeutic targets and will explore new agents that are currently being investigated. |
url |
http://dx.doi.org/10.1155/2012/682480 |
work_keys_str_mv |
AT tomokotagawa ovariancanceropportunityfortargetedtherapy AT robertmorgan ovariancanceropportunityfortargetedtherapy AT yunyen ovariancanceropportunityfortargetedtherapy AT joannemortimer ovariancanceropportunityfortargetedtherapy |
_version_ |
1725747783707656192 |